{"id":"18f-fet","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL477278","moleculeType":"Small molecule","molecularWeight":"226.24"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the amino acid transport system L, allowing for visualization of tumor cells in the brain. This is particularly useful for diagnosing and monitoring the progression of gliomas.","oneSentence":"18F-FET is a positron-emitting radiopharmaceutical used for imaging of gliomas and other brain tumors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:25:15.471Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Imaging of gliomas and other brain tumors"}]},"trialDetails":[{"nctId":"NCT07475390","phase":"NA","title":"99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tomsk National Research Medical Center of the Russian Academy of Sciences","startDate":"2026-02-15","conditions":"Glioma (Any Grade) in the Brain","enrollment":40},{"nctId":"NCT04044937","phase":"PHASE2","title":"Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms","status":"COMPLETED","sponsor":"Thomas Hope","startDate":"2018-10-29","conditions":"Intracranial Neoplasm, Low Grade Glioma, Recurrent Glioblastoma","enrollment":143},{"nctId":"NCT07463625","phase":"","title":"Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2023-11-23","conditions":"Cushing Disease, ACTH-producing Pituitary Tumour","enrollment":20},{"nctId":"NCT07456878","phase":"PHASE1","title":"Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-08","conditions":"Pituitary Adenoma","enrollment":5},{"nctId":"NCT07238322","phase":"","title":"[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-09-22","conditions":"Retrospective Study, Glioma, Brain Neoplasms","enrollment":400},{"nctId":"NCT07366710","phase":"NA","title":"Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-05","conditions":"Glucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease)","enrollment":36},{"nctId":"NCT07379463","phase":"","title":"Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases","status":"RECRUITING","sponsor":"Tianjin Medical University","startDate":"2013-08-29","conditions":"Amino-Acid Transport Disorder, Primary Hyperparathyroidism, Glioma","enrollment":500},{"nctId":"NCT05450744","phase":"PHASE1","title":"131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2023-04-01","conditions":"Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme","enrollment":12},{"nctId":"NCT06584123","phase":"NA","title":"Molecular Pituitary Imaging Using 18F-FET PET","status":"RECRUITING","sponsor":"University of Cambridge","startDate":"2024-09-03","conditions":"Pituitary Adenoma","enrollment":20},{"nctId":"NCT07108244","phase":"NA","title":"Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-10-22","conditions":"Cushing Disease","enrollment":43},{"nctId":"NCT06451042","phase":"","title":"FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2024-07-01","conditions":"Glioblastoma Multiforme","enrollment":11},{"nctId":"NCT05632562","phase":"EARLY_PHASE1","title":"Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2024-03-07","conditions":"High Grade Glioma","enrollment":20},{"nctId":"NCT05386043","phase":"","title":"Registering Genomics and Imaging of Tumors (ReGIT)","status":"RECRUITING","sponsor":"Indiana University","startDate":"2023-07-18","conditions":"Glioma","enrollment":20},{"nctId":"NCT06092125","phase":"","title":"Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2022-10-01","conditions":"Alzheimer Disease, Parkinson Disease, Epilepsy","enrollment":2300},{"nctId":"NCT04111588","phase":"","title":"Diagnostic Assessment of Amino Acid PET/MRI in the Evaluation of Glioma and Brain Metastases","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2019-11-25","conditions":"Brain Neoplasms","enrollment":160},{"nctId":"NCT06499831","phase":"NA","title":"18F-FET-PET/MRI vs Standard MRI Alone for Stereotactic RadioTherapy Planning for High Grade Brain Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-12-15","conditions":"Glioma, Malignant","enrollment":30},{"nctId":"NCT06456723","phase":"PHASE1, PHASE2","title":"Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2014-05-14","conditions":"Neuroendocrine Tumors","enrollment":56},{"nctId":"NCT06743100","phase":"","title":"18F-Floretyrosine Expanded Access Program","status":"AVAILABLE","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"","conditions":"Glioma (Any Grade) in the Brain","enrollment":""},{"nctId":"NCT06474533","phase":"","title":"Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm","status":"RECRUITING","sponsor":"Thomas Hope","startDate":"2024-06-21","conditions":"Intracranial Neoplasm","enrollment":199},{"nctId":"NCT06172595","phase":"PHASE2","title":"FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma","status":"RECRUITING","sponsor":"Singapore General Hospital","startDate":"2023-12-21","conditions":"Glioma, Malignant","enrollment":22},{"nctId":"NCT06563024","phase":"NA","title":"18F-FET PET/CT in the Management of Glioma","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2020-08-01","conditions":"Glioma","enrollment":36},{"nctId":"NCT02666547","phase":"PHASE1","title":"68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis","status":"TERMINATED","sponsor":"University of Lausanne Hospitals","startDate":"2014-03","conditions":"Pathological Angiogenesis","enrollment":42},{"nctId":"NCT03451123","phase":"EARLY_PHASE1","title":"FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2018-04-23","conditions":"Pediatric Brain Tumors","enrollment":1},{"nctId":"NCT04671459","phase":"PHASE2","title":"TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine","status":"UNKNOWN","sponsor":"Prof. Franciszek Lukaszczyk Memorial Oncology Center","startDate":"2020-12-26","conditions":"Glioblastoma Multiforme, Recurrent Glioblastoma","enrollment":40},{"nctId":"NCT05083936","phase":"NA","title":"Prospective Comparison of 18F-FDG and 18F-FET PET for Response Evaluation in Patients With Primary Central Nervous System Lymphoma","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2021-08-27","conditions":"Patients With Suspected or Diagnosed Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT04001257","phase":"","title":"18F-Fluoro-Ethyl-Tyrosine (FET) Positron Emission Tomography (PET) and Grading Glioma","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2019-06-17","conditions":"Positron Emission Tomography, Glioma","enrollment":60},{"nctId":"NCT01756352","phase":"PHASE2","title":"FET-PET for Evaluation of Response of Recurrent GBM to Avastin","status":"COMPLETED","sponsor":"Marcelo F. Di Carli, MD, FACC","startDate":"2013-02","conditions":"Glioblastoma Multiforme, GBM","enrollment":13},{"nctId":"NCT03402425","phase":"NA","title":"The Diagnostic Value of 18F-FET PET/MRI for CNS Tumors in Children and Adolescents","status":"UNKNOWN","sponsor":"Rigshospitalet, Denmark","startDate":"2015-02-24","conditions":"Positron-Emission Tomography, Brain Neoplasms, Childhood","enrollment":200},{"nctId":"NCT03370926","phase":"","title":"FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy","status":"UNKNOWN","sponsor":"University Hospital, Brest","startDate":"2016-10-31","conditions":"Glioblastoma Multiforme, Anaplastic Astrocytoma, Radiotherapy","enrollment":30},{"nctId":"NCT03216148","phase":"PHASE2","title":"18F-FET PET in Childhood Brain Tumours","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2015-07","conditions":"Brain Neoplasm","enrollment":160},{"nctId":"NCT02286531","phase":"NA","title":"Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2010-06","conditions":"Low Grade Glioma","enrollment":93},{"nctId":"NCT01579253","phase":"","title":"Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2012-04","conditions":"Glioblastoma, Nervous System Neoplasms, Central Nervous System Neoplasms","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":169,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["18F-Fluoroethyltyrosine","PET/CT"],"phase":"phase_2","status":"active","brandName":"18F-FET","genericName":"18F-FET","companyName":"Marcelo F. Di Carli, MD, FACC","companyId":"marcelo-f-di-carli-md-facc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"18F-FET is a positron-emitting radiopharmaceutical used for imaging of gliomas and other brain tumors. Used for Imaging of gliomas and other brain tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}